Adjacent Evidence Brief: Zinc Supplementation Effects

Hypothesis-Generating Brief: Zinc Supplementation Effects

Abstract

This paper synthesizes evidence on zinc supplementation effects across 32 accepted source papers and 1454 high-confidence extracted claims.

The evidence profile contains 4 direct clinical sources, 28 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the immune and inflammation, longevity outcome classes, null signals in the contextual adjacent evidence, deficiency prevalence, immune and inflammation outcome classes, and negative signals in the immune and inflammation, contextual adjacent evidence outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that zinc supplementation effects remains a bounded evidence hypothesis: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any over-broad aging-related claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

Introduction

This synthesis evaluates evidence on zinc supplementation effects across 32 included source papers and 1454 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 4 direct clinical sources, 28 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

Scope of the synthesis

This synthesis treats the topic as a structured research question rather than as a binary endorsement. The introduction therefore frames why the intervention is scientifically relevant, why the evidence base must be separated by directness and outcome class, and why mechanistic plausibility cannot substitute for clinical certainty. The public argument is intentionally bounded: it asks what the accepted evidence can support, what remains unresolved, and what kind of future study would most efficiently reduce uncertainty.

Background

The background evidence for zinc supplementation effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Barffour 2020, Baissary 2025, Wessells 2019 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the immune and inflammation, longevity outcome classes; null signals around the contextual adjacent evidence, deficiency prevalence, immune and inflammation outcome classes; and negative or adverse signals around the immune and inflammation, contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-zinc_supplementation_effects-v06-DAILY-2026-07-01T06-33-37Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-01.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• Zinc supplementation effects aging
• Zinc supplementation effects older adults
• Zinc supplementation effects randomized controlled trial
• Zinc supplementation aging
• Zinc supplementation older adults
• Zinc supplementation randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses zinc supplementation effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 174 records in the receipt-candidate union, 54 were classified as source candidates and 32 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
source candidate union	174
Classified source candidates	54
No extractable claims	4
None-only claim binding	2
Mixed partial-or-none claim-binding candidates	71
Partial-only claim-binding candidates	28
Strict high-confidence sources	15
Admitted final sources	32

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Zinc Supplementation Effects / Contextual Adjacent Evidence	n=9; claims=404	significant source statistic in 8/9 sources; receipt-level direction coded unclear	1 direct; 4 indirect; 4 review	limited corpus depth in this outcome class
Zinc Supplementation Effects / Immune and Inflammation	n=9; claims=430	significant source statistic in 9/9 sources; receipt-level direction coded unclear	3 direct; 4 indirect; 2 review	limited corpus depth in this outcome class
Zinc Supplementation Effects / Longevity	n=6; claims=170	significant source statistic in 2/6 sources; receipt-level direction coded unclear	1 indirect; 5 review	limited corpus depth in this outcome class
Zinc Supplementation Effects / Population / prevalence	n=3; claims=283	significant source statistic in 3/3 sources; receipt-level direction coded unclear	3 indirect	limited corpus depth in this outcome class
Zinc Supplementation Effects / Cardiometabolic	n=2; claims=5	significant source statistic in 1/2 sources; receipt-level direction coded unclear	2 review	limited corpus depth in this outcome class
Zinc Supplementation Effects / Dosing and Pharmacokinetics	n=2; claims=83	significant source statistic in 2/2 sources; receipt-level direction coded unclear	1 indirect; 1 review	limited corpus depth in this outcome class
Zinc Supplementation Effects / Mortality and Survival	n=1; claims=79	significant source statistic in 1/1 sources; receipt-level direction coded unclear	1 indirect	single-source slice; hypothesis-generating

Source-context map: Source-title contexts are separated for interpretation and are not pooled as one clinical effect.

• Dosing and pharmacokinetics context: 2 sources; significant source statistic in 2/2 sources; receipt-level direction coded unclear.
• Aging and geroscience context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null.
• Infectious-disease and immunology context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.
• Oncology and cancer context: 1 sources; negative signal in 1/1 sources.

Results Summary

• Contextual Adjacent Evidence: n=9; claims=404; mixed signal in 6/9 sources | directness: 1 direct; 4 indirect; 4 review; main limitation: directionally heterogeneous.
• Immune and Inflammation: n=9; claims=430; mixed signal in 4/9 sources | directness: 3 direct; 4 indirect; 2 review; main limitation: directionally heterogeneous.
• Longevity: n=6; claims=170; mixed signal in 5/6 sources | directness: 1 indirect; 5 review; main limitation: no direct clinical anchor.
• Population / prevalence: n=3; claims=283; mixed signal in 2/3 sources | directness: 3 indirect; main limitation: no direct clinical anchor.
• Cardiometabolic: n=2; claims=5; mixed signal in 2/2 sources | directness: 2 review; main limitation: no direct clinical anchor.
• Dosing and Pharmacokinetics: n=2; claims=83; mixed signal in 2/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

Two systematic reviews anchor the cardiometabolic evidence base for zinc supplementation, each pooling randomized controlled trials across heterogeneous populations. Jayawardena 2022 synthesized studies in prediabetes mellitus, while Khazdouz 2020 aggregated randomized controlled trials evaluating cardiometabolic risk factors more broadly. Both reviews summarize zinc delivered as an oral supplement, alone or in combination with other micronutrients, against comparators that varied across the included primary trials. The principal endpoints assessed were fasting and post-load glucose, glycated hemoglobin, and related metabolic indices. The two reviews together provide the principal human-evidence substrate for the cardiometabolic class within this corpus.

Per-study endpoint detail, including additional p-values, dose ranges, and follow-up durations, is catalogued in the evidence synthesis (Per-Study Endpoint Evidence). The two reviews thus converge on the direction of glycemia-related benefit while differing in the precise effect-size metric.

Mechanistically, the glycemia-related reductions are biologically plausible through zinc's role in insulin storage and secretion in pancreatic beta cells and through its contribution to antioxidant defenses relevant to insulin signaling. Preclinical data referenced in the background literature frame zinc deficiency as a state of impaired glucose tolerance, which in turn grounds the clinical RCT signal observed by Jayawardena 2022 and Khazdouz 2020. Both reviews describe their evidence as clinical RCT-derived, but each pools across populations and formulations such that the mechanistic substrate (insulin-handling and oxidative balance) cannot be tested directly at the meta-level. The mechanistic frame is therefore inferential rather than measured within the corpus.

Within-corpus tensions in the cardiometabolic class are limited: Jayawardena 2022 and Khazdouz 2020 are the two indexed sources and they do not contradict on direction. The discrepancy is one of precision rather than of sign: Jayawardena 2022's narrower confidence interval reflects its prediabetes-focused inclusion criteria, while Khazdouz 2020's broader inclusion yields wider intervals. No same-outcome non-orthogonal pairs are flagged in the cross-study disagreement map for this class, consistent with the broadly aligned but imprecisely estimated cardiometabolic picture.

Contextual Adjacent Evidence Outcomes

Because every included source maps to the contextual other outcome class, this section aggregates the corpus's clinical, programmatic, and biomarker signals under a single subsection organized by mechanism rather than by repeated outcome label. Owusu-Agyei 2013 evaluated a vitamin A + zinc combination against malaria morbidity in a community-based Ghanaian cohort. Hall-Clifford 2017 translated programmatic guidance into a Guatemalan implementation context, measuring oral rehydration therapy and zinc uptake at the community level.

Quantitative findings diverged sharply across these trials and reviews. the evidence synthesis carries the per-study × p-value tuple inventory, and the prose here references rather than restates each cell.

Mechanistically, the within-corpus pathways cluster around three substrates. The mechanistic substrate underlying this functional finding links zinc's role in immune cell signaling and epithelial repair to the disparate endpoints surveyed here, even as the directness of inference varies considerably from trial to trial.

Within-corpus tensions are most visible along two axes. By contrast, the Wessells 2019 biomarkers and the Hsu 2024 dysmenorrhea synthesis lean positive, illustrating that the contextual other class is not uniformly null or negative but stratified by endpoint, population, and trial design.

Population / prevalence Outcomes

Quantitative findings were heterogeneous across the three sources. Venneria 2014 reported P < 0.05 against an explicit null finding: 'Zn supplementation had no significant' effect on the markers measured. The mixture of significant and null or marginal p-values within each source supports the brief's framing of deficiency prevalence as a domain where null findings dominate and the boundary conditions for benefit remain to be established.

Mechanistically, the deficiency prevalence cluster sits upstream of downstream functional endpoints — correcting low plasma zinc is the precondition through which immune, redox, and gastrointestinal pathways could plausibly be modulated. Preclinical and mechanistic human data invoked across these cohorts point to zinc's role as a cofactor for antioxidant enzymes and as a structural component of immune signaling, which is consistent with the partial signals observed. By contrast, the failure of Venneria 2014 to demonstrate significant redox effects in an elderly Italian cohort without overt deficiency suggests that, when baseline zinc status is adequate, supplementation does not augment the same endpoints — a context-dependence echoed by the P = 0.086 marginal result in Chao 2023 and the mixed p-value set in Guo 2012.

Within-corpus tensions in the deficiency prevalence class are most visible when Venneria 2014 is read against the Guo 2012 hemodialysis cohort. The disagreement is consistent with population baseline status — deficiency-replete adults (Venneria 2014) gain little, whereas deficiency-confirmed dialysis patients (Guo 2012) demonstrate select positive signals — and aligns with the brief's claim that the zinc supplementation case is incomplete, with boundary conditions yet to be set.

Dosing and Pharmacokinetics Outcomes

The dosing and pharmacokinetics outcome class draws on observational and review-level evidence rather than a single confirmatory clinical RCT. Tsushima 2026 reported a dose of 15 mg. The analysis was designed to test whether escalation of mean daily elemental zinc above conventional dietary-intake ceilings translated into a survival benefit, with comparison of the three exposure bands treated as the principal contrast of interest (Tsushima 2026). Because the comparison is between exposure strata rather than against placebo, the design occupies the dosing–pharmacokinetics outcome class and is labelled as indirect for downstream survival inference (Tsushima 2026). The outcome class is therefore anchored by stratified exposure data, with effect direction recorded as unclear pending the multiplicity-adjusted results reported below.

Quantitative findings from Tsushima 2026 do not support a monotonic exposure–response relationship between zinc dose and survival. The reported between-group survival comparisons returned p-values of P = 0.303, P = 0.356, P = 0.37, P = 0.86, P = 0.64, and P = 0.85 across the pairwise contrasts evaluated, indicating no statistically detectable separation of the low, medium, and high dose strata (Tsushima 2026). A single within-cohort comparison yielded P = 0.02, which the authors did not interpret as a primary dose–response signal given the multiplicity of contrasts and the observational design (Tsushima 2026). Across the full source set, no per-study endpoint evidence table is available for dosing–pharmacokinetics because the Tsushima 2026 endpoint is a hard clinical outcome (survival) layered onto the dose-stratified analysis, rather than a pharmacokinetic parameter such as plasma zinc AUC or urinary zinc excretion (Tsushima 2026).

Mechanistically, the dosing–pharmacokinetics class sits at the interface between elemental zinc intake, systemic zinc handling, and downstream clinical endpoints, and the curated evidence here captures only the clinical extreme of that interface. Tsushima 2026 implicates acute-phase redistribution and stress-driven urinary zinc losses in severe trauma, which raises the possibility that higher enteral doses are needed simply to offset catabolic losses rather than to produce a pharmacodynamic benefit (Tsushima 2026). Pompano 2020 frames dose and duration as the two dimensions that modulate cardiometabolic risk-factor responses in type 2 diabetes, suggesting that any exposure–response curve for zinc is highly dependent on baseline status, intervention duration, and the specific risk factor selected (Pompano 2020). Because the curated corpus in this outcome class contains no human kinetic study with serial plasma or urinary zinc measurements, the mechanistic substrate underlying the null high-dose survival finding in Tsushima 2026 cannot be specified at the level of achieved systemic exposure and remains an open question for future receptor-level kinetic work (Tsushima 2026). The class is therefore best read as a boundary-condition analysis: it defines what higher doses do not appear to achieve, without specifying the pharmacokinetic target they fail to hit.

Within-corpus tensions in this outcome class are limited but informative, and are best framed as a divergence between exposure definition and clinical signal. The disagreement between these two sources is not contradictory so much as scope-dependent: Tsushima 2026 asks whether escalating mean daily dose rescues survival in a single acute indication, whereas Pompano 2020 asks whether variation in dose and duration across chronic indications shifts pooled risk-factor means. Read together, the two sources jointly argue that the absence of an effect in Tsushima 2026 should not be over-generalized to a global claim that zinc dose does not matter, and that the chronic-disease dose–response question addressed by Pompano 2020 remains the more pharmacologically tractable frame for this outcome class (Tsushima 2026; Pompano 2020).

Immune and Inflammation Outcomes

Banupriya 2017 is the single direct clinical RCT in this outcome class, randomizing adults with neonatal sepsis to adjunctive zinc supplementation or placebo and tracking serum calprotectin, IL-6, and clinical course; reductions in serum calprotectin and IL-6 were observed in both arms following antibiotic treatment (P < 0.05), without a zinc-specific separation from control. These two trials together anchor the clinical RCT layer of the immune evidence base.

Two systematic reviews and one observational cohort provide the quantitative inflammatory backdrop. Hosseini 2021 pooled adult RCTs and found that zinc supplementation lowered serum CRP with an effect size of −0.92 mg/L and a series of meta-analytic P-values (P < 0.001, P = 0.006, P = 0.04) supporting an anti-inflammatory signal. Per-study endpoint values are catalogued in the evidence synthesis.

The mechanistic substrate underlying these inflammatory findings therefore converges across the clinical RCT layer (Banupriya 2017) and the pooled adult RCT evidence (Hosseini 2021; Kim 2014): zinc appears to act as a permissive cofactor for resolution of inflammation rather than as a primary anti-inflammatory drug, which is consistent with the magnitude of effect reported in the meta-analytic estimate (ES = −0.92 mg/L).

Within-corpus tension runs along two axes. Second, Banupriya 2017 is graded as direct evidence, whereas Kemp 2024, Hamedifard 2020, Kim 2014, and Hosseini 2021 sit at varying levels of indirectness (population or review level); reading the direct neonatal-sepsis null alongside indirect pooled positives risks conflating windows of biology that may not transfer, and these directness gaps should be carried forward as a boundary condition rather than collapsed.

Four sources populate the immune and inflammation outcome class: two direct randomized trials of zinc supplementation in clinical populations (Barffour 2020; Baissary 2025) and two indirect observational or randomized studies that report inflammatory biomarkers without testing zinc as a primary anti-inflammatory intervention (Kim 2024; Long 2022). Barffour 2020 randomized rural Laotian children to therapeutic or preventive zinc regimens and tracked diarrhea and acute respiratory tract infection endpoints. Baissary 2025 was a double-blind randomized placebo-controlled trial of zinc supplementation in adults living with HIV, with inflammation and gut-integrity markers as mechanistic endpoints. Kim 2024 is a retrospective single-center observational cohort that stratified sepsis patients by received zinc dose (<15 mg, 15–50 mg, ≥50 mg).

Across all four sources, the sources themselves carry no aggregate effect size or pooled estimate, so no summary statistic is computed here.

Mechanistically, the inflammation-relevant signals cluster around two distinct human substrates. In a clinical RCT in HIV-infected adults, Baissary 2025 frames zinc supplementation as acting on systemic inflammation and gut-integrity markers, which is consistent with a barrier-and-cytokine mechanism. In a pediatric preventive RCT, Barffour 2020 anchors zinc to clinical infectious endpoints (diarrhea incidence/duration, acute respiratory tract infection), which mechanistically implicate mucosal immunity and pathogen-clearance pathways rather than systemic inflammation per se. Long 2022 contributes a metabolic-mechanistic readout (EZP pool size as a functional zinc-status marker) and tests whether that pool tracks inflammatory markers, while Kim 2024 contributes a dose-response observational readout in critically ill sepsis patients. The two RCTs therefore interrogate complementary mechanistic layers — mucosal infection outcomes and systemic inflammation/gut integrity — whereas the two indirect studies interrogate zinc-status metabolism and a critical-illness dose-response pattern.

The principal within-corpus tension in this outcome class is an indirectness gap, not a directional contradiction. Baissary 2025 and Barffour 2020 are direct randomized tests of zinc supplementation on immune or inflammatory endpoints, whereas Kim 2024 and Long 2022 contribute indirect evidence — Kim 2024 because zinc dose was a stratification variable rather than a randomized intervention, and Long 2022 because the primary mechanistic readout was EZP size, with inflammation as a secondary marker. Across the direct RCT pair, the two studies also differ in population (Laotian children vs HIV-positive adults) and in endpoint class (clinical infection vs biomarker), so their effects are not directly comparable and should be interpreted as complementary rather than confirmatory.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

Longevity Outcomes

Five curated sources converge on the question of whether zinc supplementation extends survival or reduces cause-specific mortality across age strata. The evidence base spans preschool children, under-5 cohorts, preterm or low birth weight infants, and adults with COVID-19. Two reviews address pediatric mortality directly (Fu 2013, Rouhani 2022), one evaluates neonatal enteral supplementation (Sinha 2022), one targets adult COVID-19 mortality (Tabatabaeizadeh 2022), and one addresses general pediatric prevention in developing-country settings (Yakoob 2011). Endpoint definitions diverge by cause — diarrhea-related, pneumonia-related, malaria-related, all-cause, and infection-related mortality — precluding a single pooled estimate across the corpus.

The discrepancy between these two pediatric meta-analyses on the same intervention is the central quantitative tension in this outcome class.

Neonatal and adult evidence layers on additional uncertainty. Sinha 2022 reported that moderate to low certainty evidence showed enteral zinc supplementation had little or no effect on mortality in preterm or low birth weight infants (risk ratio 0.73, 95% CI: 0.46 to 1.16). Mechanistically, the divergence between pediatric-null and adult-positive signals maps onto the immune and inflammatory pathways catalogued elsewhere in this corpus, where zinc's role in lymphocyte maturation and oxidative-stress buffering is mechanistically plausible but does not consistently translate into a survival benefit in clinical RCT settings.

Within-corpus tensions in this outcome class are best framed as a pediatric-versus-adult and a pediatric-internal disagreement. Fu 2013 and Rouhani 2022 draw on overlapping RCT pools but reach opposite headline conclusions, illustrating that pooled mortality estimates are sensitive to trial selection and analytic frame. Yakoob 2011 frames the developing-country pediatric context — diarrhea, pneumonia, malaria — in which the same RCTs feeding Fu 2013 were generated. The study was placebo-controlled and enrolled an adult population with documented heavy alcohol consumption, a contextual modifier that may condition the supplement's biological effect. Duration and dosing parameters are reported in the source material, and Veterans Aging Cohort Study Index scoring was used to capture disease trajectory. This trial constitutes the principal human-RCT signal within the outcome class in the present corpus.

Quantitative findings from the single available trial do not support a mortality benefit of zinc supplementation in this population. Effect direction is recorded as unclear within the curated set, consistent with the observation that the preponderance of these P values do not cross conventional significance thresholds and a single value (P = 0.02) is not accompanied by a clearly directional clinical outcome statement in the source. the evidence synthesis carries each per-endpoint tuple so that readers can inspect the full dispersion; the prose summary is that no consistent survival advantage was detected.

Mechanistically, a survival-relevant zinc signal would be expected to operate through pathways relevant to immune competence and inflammation rather than through direct geroprotective action, and any translation of such mechanistic substrates into mortality endpoints would plausibly require both adequate background zinc status and sustained exposure windows. The present corpus does not include dedicated mechanistic human substudies of zinc in this outcome class, so the link between pathway-level biology and the observed null survival finding remains inferential. The single RCT's heavy-alcohol-use population further complicates mechanism attribution, because alcohol itself perturbs zinc absorption and immune function. Preclinical data, where present in the broader literature, would contextualize the human finding but are not represented here as source-level evidence.

Mortality and Survival Outcomes

Within the curated corpus, no same-outcome cross-study disagreements are recorded in the matrix for the mortality and survival class, so no internal disagreement among sources needs to be adjudicated here; the corpus is thin rather than contradictory. The integrating brief characterizes survival-related findings as mixed or sparse, and the single RCT's unclear effect direction with predominantly non-significant P values is consistent with that description. The boundary conditions under which zinc supplementation might modify mortality risk (baseline deficiency status, dose, co-exposures such as alcohol) therefore remain to be established by future trials, and any clinical inference drawn from this outcome class should be limited to the indexed HIV-positive heavy-drinking adult context captured by Freiberg 2020.

Mortality and Survival remains a separate Results slice for Zinc Supplementation Effects (n=1; claims=79; significant source statistic in 1/1 sources; source-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Freiberg 2020 (Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With; representative non-significant statistic P = 0.06; not treated as positive or negative directional support unless source direction is coded; outcome=Mortality and Survival; direction=mixed; directness=indirect; tier=B2).

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

Cross-Domain Synthesis

The single most consequential cross-outcome tension in the zinc corpus is the divergence between positive mechanistic and biomarker signals on immune and immune inflammation endpoints and the essentially null mortality survival and longevity evidence. The mechanism behind the divergence is straightforward: zinc plausibly modulates T-cell maturation, cytokine balance, and barrier integrity, which should reduce infectious morbidity and inflammation markers, but the same biology does not necessarily translate into hard-outcome survival gains when background mortality drivers (heavy alcohol use, prematurity, environmental enteric dysfunction) dominate. The boundary condition appears to be baseline zinc status and the dominant cause of death in the population; signals are most coherent where deficiency is prevalent and where mortality is infection-mediated, not in already-treated HIV populations or in preterm infants where multiple micronutrient deficiencies coexist. What would resolve the tension is a mortality-powered RCT stratified by baseline plasma zinc and conducted in a clearly deficient population, paired with pre-registered biomarker-to-mortality mediation analyses, because the current source set cannot adjudicate whether the biomarker gains carry through to survival.

The conflict is direct rather than methodological, and it cannot be papered over. At the mechanism level, both populations have chronic low-grade inflammation, but the diabetic cohort in Hamedifard 2020 also has coronary heart disease, established statin/antiplatelet therapy, and is receiving a combined magnesium-zinc preparation, whereas Kim 2014 isolates zinc monotherapy in younger women without cardiovascular comorbidity. What would resolve this disagreement is a head-to-head monotherapy-versus-combination RCT with Cu/Zn ratio and ceruloplasmin as mechanistic mediators, because the two available sources disagree on direction in the same outcome class and currently the corpus offers no way to choose between them.

The third cross-domain tension is the indirectness gap that the matrix repeatedly flags: direct RCTs with mechanistic/biomarker endpoints (Baissary 2025, Barffour 2020, Wessells 2019, Banupriya 2017) sit alongside indirect observational cohorts (Kemp 2024 on maternal status, Kim 2024 on sepsis, Hamedifard 2020 on metabolic status, Tsushima 2026 on trauma dosing) and pooled meta-analyses (Hosseini 2021, Khazdouz 2020, Jayawardena 2022). It should not, and the Ioannidis 2005 surrogate-endpoint caution is precisely the relevant methodological reference here: a biomarker movement of the magnitude reported in Hosseini 2021 and Kim 2014 does not by itself license claims about functional or survival benefit in older adults. What would resolve the gap is a trial design that pre-specifies the biomarker as a surrogate with prior hard-outcome validation, or that includes a hard-outcome co-primary endpoint so the surrogate is anchored rather than freestanding.

The mechanism here is that in deficient pediatric populations zinc corrects a proximal cause of death (acute diarrhea, lower respiratory tract infection), whereas in adults the relevant causes of death are dominated by cardiovascular disease, malignancy, and chronic multimorbidity — none of which are zinc-mediated in the same direct way. The boundary condition is therefore developmental: pediatric supplementation in deficient low- and middle-income settings acts on infection-driven mortality; adult supplementation in well-nourished settings does not have the same proximal lever to pull. What would resolve the tension is an explicit age- and baseline-status-stratified individual-participant-data meta-analysis, because at present the pediatric and adult literatures are being averaged together in a way that masks what is in fact a coherent age- and deficiency-dependent gradient.

These findings sit in uneasy proximity to positive immune inflammation signals (Baissary 2025, Kim 2014) and positive cardiometabolic signals (Khazdouz 2020, Jayawardena 2022 with 2hr-OGTT reduction of 21.08 mg/dL, P = 0.03). At the mechanism level, pro-oxidant effects of zinc at high dose or in already-oxidatively-stressed tissue can plausibly explain why an agent that lowers CRP and improves glycemic markers also fails to lower, or even raises, lipid-peroxidation markers in cancer-survivor populations. The boundary condition is baseline oxidative-stress burden and dose: a tightly bounded nutritional dose (closer to the 15 mg/day arm of Venneria 2014 or the pediatric preventive range) in a non-cancer population behaves differently from a high-dose antioxidant intervention in previously treated cancer patients. What would resolve the tension is a dose-response RCT with isoprostane and CRP as co-primary biomarkers across cancer-survivor and non-cancer populations, because the current corpus contains both signals and the resolution cannot be inferred from any single source.

Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 32 curated reference papers, the evidence base for Zinc shows a context-dependent profile. Positive signals appear in: immune inflammation, longevity. Negative signals appear in: immune, contextual other. Null findings dominate: contextual other, deficiency prevalence. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Zinc anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 32 included sources. The evidence-tier distribution is: B2 (n=21), B1 (n=7), A1 (n=4). By directness, the breakdown is: indirect (n=14), review (n=14), direct (n=4). 27 of 32 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 2 distinct summaries across the source set: adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

Several outcome claims in this synthesis rest on a single trial, which means they cannot be internally replicated within the corpus. Single-trial outcomes have unknown external validity until another curated RCT reproduces them, so claims tied only to these sources can be interpreted as hypothesis-generating rather than established.

The trials enrolled in the corpus cluster in specific high-risk strata, which constrains how widely the findings can be transported. Healthy community-dwelling older adults without an underlying condition or baseline deficiency are sparsely represented, so claims about routine zinc supplementation for general adult health sit outside the populations the corpus actually tested.

Hard clinical endpoints are thinly covered relative to biomarker and intermediate endpoints. Functional endpoints that matter for an anti-aging framing — grip strength, gait speed, frailty incidence, falls, and cognitive decline — are not measured in any source in the curated set, so canonical thresholds such as the EWGSOP2 sarcopenia cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) cannot be linked to zinc effect estimates here. Endpoints the corpus does not measure therefore cannot be claimed to have improved, even when mechanistic plausibility is strong.

Several clinically-relevant claims have mechanistic evidence only, with no human-RCT outcome of the same clinical event in the curated set. Venneria 2014 reports antioxidant/red-ox effects (P < 0.05) without tracking any downstream clinical event in its Italian elderly cohort; Baissary 2025 (P < 0.01; P < 0.0001; P = 0.02) and Long 2022 (P < 0.01; P < 0.001) demonstrate reductions in HIV-related inflammation and gut-integrity markers but do not test AIDS-defining or mortality outcomes against those biomarkers in the same dataset. Mechanistic plausibility coexists here with a gap between pathway activation and clinically meaningful benefit, a pattern flagged generally by Ioannidis 2005 for surrogate endpoints, so translating these biomarker shifts into anti-aging recommendations would exceed what the corpus can support.

Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

Bounded conclusion

This synthesis supports a bounded interpretation across 32 included sources. The evidence tiers are B2 (n=21), B1 (n=7), A1 (n=4), and directness is indirect (n=14), review (n=14), direct (n=4). Effect directions are unclear (n=22), null (n=4), positive (n=3), negative (n=2), mixed (n=1), with 27 sources carrying source-traced p-values and 115 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

What This Synthesis Adds

This synthesis maps 32 included sources on Zinc Supplementation Effects across 8 outcome classes and 115 cross-study disagreements. It separates endpoint-specific evidence from broad endpoint-specific protective effects claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the disagreement between Hamedifard 2020 and Kim 2014 on immune and inflammation (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Fu 2013, Hosseini 2021, Sinha 2022, Rouhani 2022, Jayawardena 2022) emphasize convergent signals on Zinc Supplementation Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	6	positive, unclear	direct interventional hard-endpoint gap
cardiometabolic	0	2	unclear	direct interventional hard-endpoint gap
deficiency prevalence	0	3	null, unclear	direct interventional hard-endpoint gap
dosing and pharmacokinetics	0	2	unclear	direct interventional hard-endpoint gap
immune and inflammation	1	4	negative, null, positive, unclear	conflict-resolution gap
mortality and survival	0	1	unclear	direct interventional hard-endpoint gap
contextual adjacent evidence	1	8	negative, null, unclear	conflict-resolution gap
immune and inflammation	2	2	mixed, positive, unclear	replication gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct interventional hard-endpoint gap	0 direct and 6 indirect sources; direction profile: positive, unclear
P2	cardiometabolic: direct interventional hard-endpoint gap	0 direct and 2 indirect sources; direction profile: unclear
P3	deficiency prevalence: direct interventional hard-endpoint gap	0 direct and 3 indirect sources; direction profile: null, unclear
P4	dosing and pharmacokinetics: direct interventional hard-endpoint gap	0 direct and 2 indirect sources; direction profile: unclear
P5	immune and inflammation: conflict-resolution gap	1 direct and 4 indirect sources; direction profile: negative, null, positive, unclear

Next-Study Design Recommendation

The next high-yield study for Zinc Supplementation Effects should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Barffour 2020; tier=A1; directness=direct; endpoint=immune inflammation; direction=unclear; representative statistic=P = 0.002.
• Baissary 2025; tier=A1; directness=direct; endpoint=immune inflammation; direction=positive; representative statistic=P < 0.0001.
• Wessells 2019; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
• Banupriya 2017; tier=A1; directness=direct; endpoint=immune; direction=null.
• Fu 2013; tier=B1; directness=review; endpoint=longevity; direction=unclear; representative statistic=P = 0.084.
• Hosseini 2021; tier=B1; directness=review; endpoint=immune; direction=unclear; representative statistic=P < 0.001.
• Sinha 2022; tier=B1; directness=review; endpoint=longevity; direction=unclear.
• Rouhani 2022; tier=B1; directness=review; endpoint=longevity; direction=unclear.
• Jayawardena 2022; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.03.
• Khazdouz 2020; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Barffour 2020: outcome=immune inflammation; directness=direct; tier=A1; direction=unclear; claims=107.
• Baissary 2025: outcome=immune inflammation; directness=direct; tier=A1; direction=positive; claims=53.
• Wessells 2019: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=52.
• Banupriya 2017: outcome=immune; directness=direct; tier=A1; direction=null; claims=1.
• Fu 2013: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=41.
• Hosseini 2021: outcome=immune; directness=review; tier=B1; direction=unclear; claims=10.
• Sinha 2022: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=6.
• Rouhani 2022: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=5.
• Jayawardena 2022: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=3.
• Khazdouz 2020: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=2.
• Kim 2014: outcome=immune; directness=review; tier=B1; direction=positive; claims=2.
• Venneria 2014: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=null; claims=206.
• Kemp 2024: outcome=immune; directness=indirect; tier=B2; direction=unclear; claims=94.
• Oh 2020: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=94.
• Yakoob 2011: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=94.
• Hamedifard 2020: outcome=immune; directness=indirect; tier=B2; direction=negative; claims=91.
• Freiberg 2020: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=79.
• Patel 2011: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=61.
• Chao 2023: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=unclear; claims=58.
• Kim 2024: outcome=immune inflammation; directness=indirect; tier=B2; direction=mixed; claims=47.
• Tsushima 2026: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=47.
• Hsu 2024: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=43.
• Pompano 2020: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=unclear; claims=36.
• Owusu-Agyei 2013: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=34.
• Hall-Clifford 2017: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=33.
• Smailhodzic 2014: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=32.
• Freitas 2015: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=30.
• Chavez-Tapia 2013: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=25.
• Long 2022: outcome=immune inflammation; directness=indirect; tier=B2; direction=unclear; claims=25.
• Guo 2012: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=unclear; claims=19.
• Mayo-Wilson 2014: outcome=longevity; directness=review; tier=B2; direction=unclear; claims=18.
• Tabatabaeizadeh 2022: outcome=longevity; directness=review; tier=B2; direction=positive; claims=6.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 5 disagreement: Hamedifard 2020 vs Kim 2014; Hamedifard 2020 reports negative effect on immune; Kim 2014 reports positive on the same outcome — direct conflict
• Severity 4 null vs negative: Freitas 2015 vs Hall-Clifford 2017; Freitas 2015 (negative on contextual other) vs Hall-Clifford 2017 (null on contextual other) — partial conflict
• Severity 4 null vs negative: Freitas 2015 vs Oh 2020; Freitas 2015 (negative on contextual other) vs Oh 2020 (null on contextual other) — partial conflict
• Severity 3 indirectness gap: Kemp 2024 vs Banupriya 2017; Banupriya 2017 (direct, A1) vs Kemp 2024 (indirect) on immune — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Kim 2024 vs Baissary 2025; Baissary 2025 (direct, A1) vs Kim 2024 (indirect) on immune inflammation — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Kim 2024 vs Barffour 2020; Barffour 2020 (direct, A1) vs Kim 2024 (indirect) on immune inflammation — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Hsu 2024 vs Wessells 2019; Wessells 2019 (direct, A1) vs Hsu 2024 (review) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Baissary 2025 vs Long 2022; Baissary 2025 (direct, A1) vs Long 2022 (indirect) on immune inflammation — direct vs indirect must be kept separate

References

• Venneria 2014. Antioxidant effect of zinc supplementation on both plasma and cellular red-ox status markers in a group of elderly Italian population. The Journal of Nutrition, Health & Aging, 2014. DOI: 10.1007/s12603-014-0005-7 PMID: 24676313.
• Barffour 2020. Effects of therapeutic zinc supplementation for diarrhea and two preventive zinc supplementation regimens on the incidence and duration of diarrhea and acute respiratory tract infections in rural Laotian children: A randomized controlled trial. Journal of Global Health, 2020. DOI: 10.7189/jogh.10.010424 PMID: 32612816.
• Kemp 2024. Zinc Supplementation Initiated Prior to or During Pregnancy Modestly Impacted Maternal Status and High Prevalence of Hypozincemia in Pregnancy and Lactation: The Women First Preconception Maternal Nutrition Trial. The Journal of Nutrition, 2024. DOI: 10.1016/j.tjnut.2024.04.018 PMID: 38621624.
• Yakoob 2011. Preventive zinc supplementation in developing countries: impact on mortality and morbidity due to diarrhea, pneumonia and malaria. BMC Public Health, 2011. DOI: 10.1186/1471-2458-11-S3-S23 PMID: 21501441.
• Oh 2020. Vitamin and Mineral Supplementation During Pregnancy on Maternal, Birth, Child Health and Development Outcomes in Low-and Middle-Income Countries: A Systematic Review and Meta-Analysis. Nutrients, 2020. DOI: 10.3390/nu12020491 PMID: 32075071.
• Hamedifard 2020. The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Lipids in Health and Disease, 2020. DOI: 10.1186/s12944-020-01298-4 PMID: 32466773.
• Freiberg 2020. Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With Heavy Alcohol Use. JAMA Network Open, 2020. DOI: 10.1001/jamanetworkopen.2020.4330 PMID: 32383748.
• Patel 2011. What zinc supplementation does and does not achieve in diarrhea prevention: a systematic review and meta-analysis. BMC Infectious Diseases, 2011. DOI: 10.1186/1471-2334-11-122 PMID: 21569418.
• Chao 2023. Zinc Deficiency and Therapeutic Value of Zinc Supplementation in Pediatric Gastrointestinal Diseases. Nutrients, 2023. DOI: 10.3390/nu15194093 PMID: 37836377.
• Baissary 2025. Zinc Supplementation, Inflammation, and Gut Integrity Markers in HIV Infection: A Randomized Placebo-Controlled Trial. Nutrients, 2025. DOI: 10.3390/nu17101671 PMID: 40431411.
• Wessells 2019. Impact of Daily Preventive Zinc or Therapeutic Zinc Supplementation for Diarrhea on Plasma Biomarkers of Environmental Enteric Dysfunction among Rural Laotian Children: A Randomized Controlled Trial. The American Journal of Tropical Medicine and Hygiene, 2019. DOI: 10.4269/ajtmh.19-0584 PMID: 31889508.
• Kim 2024. Effectiveness of Zinc Supplementation for Sepsis Treatment: A Single-Center Retrospective Observational Study. Nutrients, 2024. DOI: 10.3390/nu16172841 PMID: 39275159.
• Tsushima 2026. High-Dose Zinc Supplementation Therapy Does Not Improve Survival Rates in Severe Trauma Patients: A Single-Center Retrospective Observational Study. Nutrients, 2026. DOI: 10.3390/nu18030541 PMID: 41683363.
• Hsu 2024. Efficacy of Zinc Supplementation in the Management of Primary Dysmenorrhea: A Systematic Review and Meta-Analysis. Nutrients, 2024. DOI: 10.3390/nu16234116 PMID: 39683510.
• Fu 2013. Effects of Zinc Supplementation on the Incidence of Mortality in Preschool Children: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2013. DOI: 10.1371/journal.pone.0079998 PMID: 24244591.
• Pompano 2020. Effects of Dose and Duration of Zinc Interventions on Risk Factors for Type 2 Diabetes and Cardiovascular Disease: A Systematic Review and Meta-Analysis. Advances in Nutrition, 2020. DOI: 10.1093/advances/nmaa087 PMID: 32722790.
• Owusu-Agyei 2013. Impact of vitamin A with zinc supplementation on malaria morbidity in Ghana. Nutrition Journal, 2013. DOI: 10.1186/1475-2891-12-131 PMID: 24330422.
• Hall-Clifford 2017. From guidelines to local realities: evaluation of oral rehydration therapy and zinc supplementation in Guatemala. Revista Panamericana de Salud Pública, 2017. DOI: 10.26633/RPSP.2017.8 PMID: 28444008.
• Smailhodzic 2014. Zinc Supplementation Inhibits Complement Activation in Age-Related Macular Degeneration. PLoS ONE, 2014. DOI: 10.1371/journal.pone.0112682 PMID: 25393287.
• Freitas 2015. High 15-F 2t -Isoprostane Levels in Patients with a Previous History of Nonmelanoma Skin Cancer: The Effects of Supplementary Antioxidant Therapy. BioMed Research International, 2015. DOI: 10.1155/2015/963569 PMID: 26509174.
• Chavez-Tapia 2013. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutrition Journal, 2013. DOI: 10.1186/1475-2891-12-74 PMID: 23742732.
• Long 2022. Exchangeable Zinc Pool Size Reflects Form of Zinc Supplementation in Young Children and Is Not Associated with Markers of Inflammation. Nutrients, 2022. DOI: 10.3390/nu14030481 PMID: 35276840.
• Guo 2012. Effects of Zinc Supplementation on Plasma Copper/Zinc Ratios, Oxidative Stress, and Immunological Status in Hemodialysis Patients. International Journal of Medical Sciences, 2012. DOI: 10.7150/ijms.5291 PMID: 23289009.
• Mayo-Wilson 2014. Preventive zinc supplementation for children, and the effect of additional iron: a systematic review and meta-analysis. BMJ Open, 2014. DOI: 10.1136/bmjopen-2013-004647 PMID: 24948745.
• Hosseini 2021. Zinc supplementation is associated with a reduction in serum markers of inflammation and oxidative stress in adults: A systematic review and meta-analysis of randomized controlled trials. Cytokine, 2021. DOI: 10.1016/j.cyto.2020.155396 PMID: 33333394.
• Tabatabaeizadeh 2022. Zinc supplementation and COVID-19 mortality: a meta-analysis. European Journal of Medical Research, 2022. DOI: 10.1186/s40001-022-00694-z PMID: 35599332.
• Sinha 2022. Enteral Zinc Supplementation in Preterm or Low Birth Weight Infants: A Systematic Review and Meta-analysis. Pediatrics, 2022. DOI: 10.1542/peds.2022-057092j PMID: 35921675.
• Rouhani 2022. Effect of zinc supplementation on mortality in under 5-year children: a systematic review and meta-analysis of randomized clinical trials. Eur J Nutr, 2022. DOI: 10.1007/s00394-021-02604-1 PMID: 34120246.
• Jayawardena 2022. Zinc supplementation in prediabetes mellitus. Minerva Endocrinol (Torino), 2022. DOI: 10.23736/s2724-6507.21.03234-x PMID: 33759442.
• Kim 2014. Effect of zinc supplementation on inflammatory markers and adipokines in young obese women. Biol Trace Elem Res, 2014. DOI: 10.1007/s12011-013-9885-3 PMID: 24402636.
• Khazdouz 2020. Effects of Zinc Supplementation on Cardiometabolic Risk Factors: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Biol Trace Elem Res, 2020. DOI: 10.1007/s12011-019-01870-9 PMID: 31494808.
• Banupriya 2017. Efficacy of zinc supplementation on serum calprotectin, inflammatory cytokines and outcome in neonatal sepsis - a randomized controlled trial. J Matern Fetal Neonatal Med, 2017. DOI: 10.1080/14767058.2016.1220524 PMID: 27491377.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169 PMID: 30312372.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (methodological reference) DOI: 10.1371/journal.pmed.0020124 PMID: 16060722.